Shahram Kordasti, Professor of Systems Cancer Immunology at King’s College London and Clinical Haemato-Oncologist at Guy’s and St Thomas’ NHS Foundation Trust, shared a post on X:
“During our recent visit to Tianjin, China, I joined the King’s College London delegation to Tianjin Medical University Cancer Institute and Hospital, one of China’s largest specialist cancer centers, with major capacity in cancer care, research and education.
One of the main reasons for the visit was to renew the collaboration agreement between King’s and Tianjin. The agreement was signed in a ceremony with the leadership teams from both institutions, together with representatives from the British Embassy in China.
These partnerships are increasingly important. For Tianjin, they create opportunities for exchange of expertise, training, student mobility and participation in major clinical and translational research programs. For King’s, they provide access to large, well-characterized patient cohorts, valuable clinical and genomic data, and high-throughput research infrastructure that can be difficult to achieve at the same scale in Europe.
This is a genuinely mutually beneficial collaboration, with the shared aim of advancing cancer research and improving patient care. The signing took place on the first day of our visit and was followed by the third joint symposium on cancer research, which I will write about separately.”
Other article about King’s College London on OncoDaily.
